Population pharmacokinetic modeling of GS‐441524, the active metabolite of remdesivir, in Japanese COVID‐19 patients with renal dysfunction

MLA

Asami Sukeishi, et al. “Population Pharmacokinetic Modeling of GS‐441524, the Active Metabolite of Remdesivir, in Japanese COVID‐19 Patients with Renal Dysfunction.” CPT: Pharmacometrics & Systems Pharmacology, vol. 11, no. 1, Jan. 2022, pp. 94–103. EBSCOhost, https://doi.org/10.1002/psp4.12736.

APA

Asami Sukeishi, Kotaro Itohara, Atsushi Yonezawa, Yuki Sato, Katsuyuki Matsumura, Yoshiki Katada, Takayuki Nakagawa, Satoshi Hamada, Naoya Tanabe, Eishi Imoto, Shinichi Kai, Toyohiro Hirai, Motoko Yanagita, Shigeru Ohtsuru, Tomohiro Terada, & Isao Ito. (2022). Population pharmacokinetic modeling of GS‐441524, the active metabolite of remdesivir, in Japanese COVID‐19 patients with renal dysfunction. CPT: Pharmacometrics & Systems Pharmacology, 11(1), 94–103. https://doi.org/10.1002/psp4.12736

Chicago

Asami Sukeishi, Kotaro Itohara, Atsushi Yonezawa, Yuki Sato, Katsuyuki Matsumura, Yoshiki Katada, Takayuki Nakagawa, et al. 2022. “Population Pharmacokinetic Modeling of GS‐441524, the Active Metabolite of Remdesivir, in Japanese COVID‐19 Patients with Renal Dysfunction.” CPT: Pharmacometrics & Systems Pharmacology 11 (1): 94–103. doi:10.1002/psp4.12736.